RapCov Rapid COVID-19 Test Instructions For Use

: June 2, 2024
: Advaite

Catalogue No. A-RAPCOV01

INTENDED USE

The RapCov™ Rapid COVID-19 Test is an in vitro diagnostic test for the qualitative detection of IgG antibodies to the COVID-19 virus in human whole blood fingerstick samples collected in CLIA certified laboratories and/or by healthcare workers at the
point-of-care. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating
under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. Results from the RapCov™ Rapid COVID-19 Test should not be used as the sole basis for diagnosis. Negative results do not preclude COVID-19 virus infection and should not be used as the sole basis for patient management decisions. Positive results are presumptive and may be confirmed by viral nucleic acid detection by RT-PCR for confirmation of COVID-19 virus infection. False positive results for IgG antibodies may occur due to cross- reactivity from preexisting antibodies to other coronaviruses or other possible causes. FDA review for
Emergency Use Authorization (EUA) for the RapCov Rapid COVID-19 Test is in progress.

INTRODUCTION

The virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), also known as “the COVID-19 virus”, causes the Coronavirus Disease (COVID19). There has been an outbreak of respiratory disease caused by a COVID-19 virus that was first detected in China. Reported illnesses have ranged from very
mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, reports suggests serious illness occurs in 20% of cases.
In the RapCov™ Rapid COVID-19 Test, presence of IgG antibodies to COVID-19 virus are determined using fingerstick whole blood. IgG antibodies are detected after the first week following the onset of symptoms.

KIT COMPONENTS

Each kit contains the following components in sufficient quantities to perform the number of tests indicated on the package label.

25 x Test Cassette Pouches. Each pouch contains one test cassette.
25 x Sample Collector Pouches. Each pouch contains one TRUEplus Pressure-Activated Safety Lancet (28G Needle, 1.6 mm Depth, Single Drop), one MicroSafe® pipette, one alcohol swab, and one dropper containing buffer solution.
1 x Instructions for Use.

MATERIALS REQUIRED BUT NOT SUPPLIED

Timer
Gloves

PRINCIPLE

When present in the patient sample, COVID-19 specific IgG antibodies bind to antihuman antibodies (IgG) immobilized in a line across the RapCov™ cassette membrane. Colloidal gold complexes containing recombinant COVID-19 nucleocapsid antigens are captured by the patient’s IgG antibodies to give a visible pink line. A procedural control is included to indicate that the assay has been performed correctly and is valid.

REPORTING

The RapCov™ test does not produce an actual test report. The testing laboratory or health care workers at point-of-care must include the test result information in their report.

PRECAUTIONS

All human blood products should be handled as potentially infectious material. The Centers for Disease Control and the National Institutes of Health recommend that potentially infectious agents be handled at Biosafety Level 2.
Never pipette by mouth or allow reagents or patient sample to come into contact with skin.
Optimal results will be obtained by strict adherence to this protocol. Reagents must be added carefully to maintain precision and accuracy.
Performing the assay outside the prescribed time and temperature ranges may produce invalid results. Assays not falling within the established time and temperature ranges must be repeated.
The components in this kit have been quality control tested as a master lot unit.
Do not mix components from different lot numbers.
Do not mix with components from other manufacturers.
Care should be exercised to protect the reagents in this kit from contamination.
Do not use if there is evidence of microbial contamination or precipitation.
Biological contamination of dispensing equipment, containers or reagents can lead to false results.
Do not heat-inactivate samples.
Keep storage boxes dry.
Do not reuse test cassettes.
Do not use test cassettes if foil pouch is punctured or damaged.
Testing materials should be disposed of in accordance with local, state and/or federal regulations.

STORAGE AND SHELF LIFE OF REAGENTS

The RapCov Rapid COVID-19 IGG Test can be shipped and distributed under room temperature.
The shelf life of RapCov Rapid COVID-19 IgG Test is 5 months at room temperature or 9 months at 2~8°C.Do not freeze kit components.
If stored at 2-8˚C, ensure that the kit is brought to 15-30˚C before opening.
The test kit may be used until the expiry date marked on the package label.

SPECIMEN COLLECTION AND PREPARATION

Blood sample is obtained by fingerstick using TRUEplus Safety Lancet and collected using MicroSafe® pipette.

1. TRUEplus Safety Lancet Procedure for Fingerstick

a) Health care provider washes hands thoroughly and put on gloves
b) Health Care provider selects the fingerstick site: The patient should be sitting or lying down. Have patient hold their hand in a downward position, allowing gravity to help increase blood supply to the hand. Select finger: middle or ring finger is preferable. The fifth finger must not be punctured because the tissue depth is insufficient to prevent bone injury.
c) Disinfect the fingerstick site: Cleanse the puncture site using an
alcohol pad or according to your facility’s established procedure.

Fingerstick

Step 1: Twist off the tab to break the seal and discard the cap. Please do not directly pull off the protective cap.
Step 2: Perform the puncture. Position the safety lancet firmly against the puncture site as illustrated. Hold lancet between fingers. To activate, press safety lancet firmly against the puncture site.
Step 3: Let blood sample form. Discard used safety lancet into a sharps container according to your facility’s established procedures.

2. Procedure for Collecting Blood Specimen Using MicroSafe® pipette

a) Squeeze gently going along finger capillaries up to the puncture site to produce a blood drop on the fingertip.
b) Hold the tube horizontally, and touch the tip of the MICROSAFE® Tube to the blood sample. Capillary action will automatically draw the sample to the air vent and it will stop.

Fingerstick

CAUTION! Filling is automatic: Never squeeze the tube while sampling.
Don’t squeeze the bulb; MICROSAFE® fills by capillary action.

Fingerstick

c) To Expel the sample, align the tip of the tube with the sample target and squeeze the bulb. If a sample won’t expel, you probably didn’t allow for the tube to fill all the way. Touch the tip of the blood sample again and allow it to fill completely. Then align the tip with the sample and squeeze the bulb.

ASSAY PROCEDURE:

_ NOTE: Ensure all reagents are equilibrated to room temperature (20-25°C) _before commencing the assay.
Remove the cassette and buffer dropper from the pouch just prior to
use.

Add whole blood to the oval sample well (S) using the MicroSafe® pipette. Allow the sample to absorb entirely into the specimen pad within the sampler well.
Open the buffer dropper by twisting off the top. Hold the buffer dropper vertically and 1 cm above the oval sample well (S). Add 2 drops of buffer to the sample well.
Read the result exactly 15 minutes after adding the buffer to the cassette. Any trace of a pink line in the rectangular test area window indicates a positive result. Do not read results after 20 minutes. Discard the test device after recording the test results.

Instructions

QUALITY CONTROL

The test is invalid and should be repeated if the control line does not appear. If the test is invalid, patient results cannot be reported.
Whole blood samples may cause a red background to appear in the viewing window. If this is not masking the test line, the result remains valid.
Quality Control (QC) requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and your laboratory’s standard QC procedures.

INTERPRETATION OF RESULTS

COVID-19 infection is characterized by the presence of detectable IgG antibodies one week after the onset of symptoms.

RESULTS IN THE RECTANGULAR TEST AREA WINDOW

C ontrol: (Top line) IgG: (Bottom line)

Positive Test

Pink bands appear in the Control (top line) and IgG (bottom line). The test is positive for IgG antibodies to COVID19 virus.

Negative Test

Negative

Pink bands appear in the Control (top line) only. The negative test does not exclude COVID-19 infection.

Invalid Test

No pink band appear in the Control (top line). The test is invalid and should be repeated.

TEST LIMITATIONS

Results from antibody testing should not be used as the sole basis to diagnose or exclude COVID-19 infection or to inform infection status.
Positive results may be due to past or present infection with non-COVID-19 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Not for the screening of donated blood
For prescription use only.
Testing is limited to laboratories or by healthcare workers at the point-of-care.
In early infections detectable levels of IgG antibodies may be low. Some patients may not produce detectable levels of antibody within the first week after infection. Where symptoms persist, patients should be re-tested 3-4 days after the first specimen.
Serological cross-reactivity across the Coronavirus group has not been tested

TROUBLESHOOTING GUIDE

PERFORMANCE EVALUATION DATA

STUDY #1: Clinical Performance Evaluation

a. Methodology: The evaluation was performed in US using fingerstick whole blood specimen (n=30) from patients who had COVID-19 disease confirmed with molecular analysis. Control fingerstick blood samples (n=99) were obtained from healthy subjects confirmed to be antibody negative. Fingerstick whole blood samples were tested using RapCov™ Rapid COVID-19 Test per the manufacturer’s Instruction for Use (IFU). Positive RapCov™ test was defined as presence of IgG COVID19 antibodies.
b. Results: Positive Percent Agreement (PPA) was 90% with RT-PCR positive COVID-19 virus infection and Negative Percent Agreement (NPA) was 100%.

Performance Evaluation

STUDY #2: Cross-Reactivity Evaluation

STUDY #2: Cross-Reactivity Evaluation
a. Methodology: Cross-reactivity evaluation was performed using human serum specimen from patients who had human coronavirus OC43 infection (n=14). Serum samples of patients who had high priority organisms were obtained and crossreactivity experiments performed. Following serum samples were obtained: (i) Influenza A; (ii) Influenza B; (iii) anti-HBV; (iv) anti-HCV ; (v) Antinuclear antibodies (ANA); (vi) Haemophilus Influenzae; (vii) Rhinovirus; (viii) anti-respiratory syncytial virus; and (ix) anti-HIV.
b. Results: Thirteen (93%) OC43 samples tested negative for IgG, thus showing minimal cross-reactivity with coronavirus OC43 infection. Serum specimen from all tested high priority organisms (Influenza A, influenze B, anti-HBV, anti-HCV, ANA and Haemophilus Influenzae, Rhinovirus, anti- respiratory syncytial virus, and antiHIV) were negative. Thus, no crossreactivity was observed with the tested high priority organism serum specimen.